Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
abiraterone acetate, Quantity: 250 mg
Janssen-Cilag Pty Ltd
Abiraterone acetate
Tablet
Excipient Ingredients: colloidal anhydrous silica; povidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium
Oral
120 tablets
(S4) Prescription Only Medicine
JANSSEN ABIRATERONE is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or ? patients with mCRPC who have received prior chemotherapy containing a taxane.
Visual Identification: White to off-white, oval shaped tablets with "AA250" on one side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2012-03-01